About Simcere：Simcere Pharmaceutical Group Limited (2096.HK) is a pharmaceutical company driven by innovative R&D and committed to synergistic innovation. Global Innovative DrugsSimcere prioritizes the R&D of innovative drugs and generic drugs with high technical barriers based on ever-increasing and unmet clinical needs. Sanbexin: the world's only innovative drug approved for stroke since 2015, which can significantly reduce CNS damage caused by acute ischemic stroke2. Specifically, the revenue of innovative drugs increased by more than 50% over the same period, occupying 62.4% of the total revenue that hits a record high. Global R&D ProfessionalsSimcere has been continuously expanding its R&D investments.

Source: Forbes October 06, 2022 15:12 UTC